valu usd unless otherwis note
updat deal analysi meet
manag today question
view updat deal analysi follow yesterday joint
myl/pf call deal dynam feed bull bear
add stabil trade-off slower growth newco also bring new
manag re-domicil back us debat investor
worth rais price target sever question
meet newco manag today
think deal add valu myl pre-deal
valuat ev/ebitda still impli per share roughli
stock close yesterday see exhibit set floor
think trade line teva modestli
lower us gener exposur limit opioid liabil risk cleaner
leverag profil anticip dividend rang
would worth per share clearli flashi deal one
move innov growth curv think push
share higher per updat pro-forma model exhibit
model newco ebitda billion lower
initi anticip put ev/ebitda net
leverag detail earli thought link confer call
takeaway includ bull/bear link follow model updat
rais pt maintain outperform rate question
quantifi modest moder revenu growth
growth organ newco see pfe/upjohn product
grow top product guid consensu model
flat think oper leverag
margin stabil keep ebitda growth line revenu
newco expect leverag end
dividend pay-out least potenti initi
repurchas timeso balanc major
call detail execut chairman focu
next one two step unlock valu call
cost synergi come quantifi
oper expens versu cost sale geographi
revenu opportun specif opportun
see long take shift product revenu across differ
plan alloc sg invest percentag
newco revenu total across three geographi asia
pacif emerg market develop market degre
priorit busi develop across region
specif target model term intern develop
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case scenario see stock price impli
price-to-earnings ep
announc combin pfe upjohn off-
patent busi grow diversifi myl revenu
base beyond us gener term agreement
holder combin entiti newco
domicil us govern delawar
law invest thesi larg unchang
pre-announc one best generic/
biosimilar pipelin industri believ
deliv above-averag growth moreov cautious
optimist newco deliv posit chang
corpor govern perspect need born
follow primari driver outperform
thesi stock
face mani sector headwind
pressur peer given diversif activ
reposit think see growth improv
come year
sever import pipelin catalyst
myl/upjohn newco trade combin ebitda
drive support improv sentiment
full synergi captur
long-term growth outlook appear stabl increasingli
steadi new gener approv activ high-single-digit
us gener eros base busi
continu ramp recent new product launch
gener copaxon fulphila gener advair
plan combin pfe upjohn busi
add diversif creat signific
oper effici greater scale target
least billion annual cost synergi
risk view delay around pipelin convers and/
lower expect uptak new launch
impair us base busi risk anoth step-
ebitda contribut delay upjohn deal close
and/or integr issu prevent newco hit
financi target inopportun use cash boost
upcom potenti catalyst event focu
deal close pfe upjohn busi expect
launch progress major new launch eg gener
copaxon fulphila wixela addit accret use
capit debt pay-down
upsid scenario see valu impli price-to-earnings
ep
myl/upjohn newco trade combin ebitda
higher expect synergi captur
inflect higher gener approv activ continu
limit competit high-valu gener greater-
downsid scenario see valu impli price-to-earnings
ep
myl/upjohn trade combin ebitda
greater competit pressur across us gener
portfolio lead lower expect new launch uptak
slowdown ou fail off-set pressur us
failur maintain steadi pipelin convers off-set
updat pro-forma analysi impli valuat floor per share
exhibit updat pro-forma analysi follow formal deal announc see valuat floor newco
forma current pro forma adj ebitda upjohn pro forma revenu upjohn pro forma adj ebitda combin pro forma revenu add cost per year reach least billion total combin pro-forma adj ebitda forma ebitda margin depreci actual upjohn estimateless legaci lless newco assum cost newco debtpre-tax incom assum tax re-domicil us current ratesassum tax net incom share count impli base pro forma ownershipnewco forma legaci deal accret per share assumptionscom share current share price share current share outstand newco deal specif newco share impli share count base state post deal ownershipimpli equiti valu pre-deal valuat levelimpli equiti valu equiti valu teva valuat levelimpli equiti valu structurecom exist net new debt total newco net debt target total debt close consist paydown cf forma capit leverag end exhibit stand-alone
 incom guid hsd growth north guid msd growth eurest guid msd growth rowoth gener total revenu guid billioncost gross profit guid guid total revenuessg guid total revenuesoper incom incom incom tax incom guid incom prefer dividend adjust net guid billionep adjust guid dilut share guid million guid billion growth ebitda analysi margin guid guid total guid total revenuesoper expens guid net incom pharmaceuticals/specialti
price target base ev/ebitda multipl appli pro-forma newco
ebitda estim modestli valuat level trade pre-
deal announc sector histor averag multipl reflect
continu challeng industri impli return price target opportun
upsid support outperform rate
risk rate price target
risk rate price target includ limit delay around pipelin
convers slower expect new launch uptak impair us
base busi delay upjohn deal close and/or integr issu inopportun
use cash boost leverag and/or impair sharehold valu
lead global gener manufactur base pittsburgh pennsylvania employ
approxim peopl global compani found transform
last sever year notabl acquisit merck kgaa
compani benefit differ revenu sourc help grow
eu auster headwind us comp strength recent year
